Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock [Yahoo! Finance]
Viridian Therapeutics, Inc. (VRDN)
Company Research
Source: Yahoo! Finance
developing potential best-in-class medicines for serious and rare diseases, today announced the pricing of an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, shares of Series B non-voting convertible preferred stock. Viridian is selling a total of 10,666,600 shares of common stock at a public offering price of $18.75 per share and 20,000 shares of Series B non-voting convertible preferred stock at a public offering price of $1,250.06250 per share, which are convertible into 1,333,400 shares of common stock, subject to beneficial ownership conversion limits. In addition, Viridian has granted the underwriters a 30-day option to purchase an additional 1,800,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Viridian from the offering are expected to be approximately $225.0 million, before deducting underwriting discounts and commissions and estimated offe
Show less
Read more
Impact Snapshot
Event Time:
VRDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRDN alerts
High impacting Viridian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VRDN
News
- Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $44.00 price target on the stock.MarketBeat
- Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its price target raised by analysts at Royal Bank of Canada from $35.00 to $44.00. They now have an "outperform" rating on the stock.MarketBeat
- Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $25.00 to $31.00. They now have a "buy" rating on the stock.MarketBeat
- Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred StockBusiness Wire
- Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its price target raised by analysts at Needham & Company LLC from $30.00 to $38.00. They now have a "buy" rating on the stock.MarketBeat
VRDN
Earnings
- 8/8/24 - Miss
VRDN
Sec Filings
- 9/17/24 - Form 4
- 9/17/24 - Form SC
- 9/13/24 - Form 424B5
- VRDN's page on the SEC website